A Phase 1 interventional study of Cilostazol and Acetylsalicylic acid in Healthy, sponsored by Otsuka Pharmaceutical Co., Ltd.. Completed at 1 site in Germany. Open to male participants aged 18 Years to 45 Years, including healthy volunteers. Per ClinicalTrials.gov, last updated 2021-10-13.
Sponsored by Otsuka Pharmaceutical Co., Ltd. (part of Otsuka Holdings Co., Ltd.) · Phase 1, Interventional, and Treatment
Help build ClinicalTrials.gg — short surveys, remote interviews or testing, in your language. Take part →
The primary objective of this study is to investigate the effects of Cilostazol, Acetylsalycylic acid and Clopidogrel alone as well as combinations of Cilostazol/Acetylsalicylic acid and Cilostazol/ Clopidogrel on ex-vivo Platelet Function (PF) testing.
Otsuka Pharmaceutical Co., Ltd. is the lead sponsor of 143 studies on the registry; 11 are open to participants now.
Counted across the registry records on this site, refreshed daily.
Go through the criteria one by one — yes, no or not sure — and take the list to your doctor or the study team. Kept in this browser only.
Exclusion Criteria:
Underlined terms in the criteria open these too. Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.
Before you join, the study team explains what taking part involves — its purpose, what happens, the risks and possible benefits — and answers your questions, so you can decide freely. Consent is usually recorded on a form (the informed consent form, ICF) signed by you or, where the law allows, by someone legally authorized to decide for you.
You can keep asking questions during the study, you are told of new information that matters, and you can choose to leave at any time.
Weight in kilograms divided by height in metres squared. Example: 70 kg and 1.75 m gives 70 ÷ (1.75 × 1.75) ≈ 22.9.
What counts as overweight or obesity differs between countries (some use lower cut-offs), so go by the range the study states.
A recording of the heart’s electrical activity, taken with stickers on the chest, arms and legs. It takes a few minutes and does not hurt.
Judged by the study doctor to matter for your health or for the study. It is a doctor’s decision, so ask the study team if you are unsure whether something counts.
Informed consent
Before you join, the study team explains what taking part involves — its purpose, what happens, the risks and possible benefits — and answers your questions, so you can decide freely. Consent is usually recorded on a form (the informed consent form, ICF) signed by you or, where the law allows, by someone legally authorized to decide for you.
You can keep asking questions during the study, you are told of new information that matters, and you can choose to leave at any time.
Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.
BMI (body mass index)
Weight in kilograms divided by height in metres squared. Example: 70 kg and 1.75 m gives 70 ÷ (1.75 × 1.75) ≈ 22.9.
What counts as overweight or obesity differs between countries (some use lower cut-offs), so go by the range the study states.
Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.
ECG (electrocardiogram)
A recording of the heart’s electrical activity, taken with stickers on the chest, arms and legs. It takes a few minutes and does not hurt.
Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.
Clinically significant
Judged by the study doctor to matter for your health or for the study. It is a doctor’s decision, so ask the study team if you are unsure whether something counts.
Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.
Trial period A: Cilostazol 100 mg twice daily for 1 week (Days 1-7) Trial period B: Wash out period (Days 8-14) Trial period C: Acetylsalicylic acid 100 mg once daily for 1 week (Days 15-21) Trial period D: Cilostazol 100 mg twice daily and Acetylsalicylic acid 100mg once daily for 1 week (Days 22-28)
Drug: Cilostazol · Drug: Acetylsalicylic acid
Trial period A: Cilostazol 100 mg twice daily for 1 week (Days 1-7) Trial period B: Wash out period (Days 8-14) Trial period C: Clopidogrel 75 mg once daily for 1 week (Days 15-21) Trial period D: Cilostazol 100 mg twice daily and Clopidogrel 75 mg once daily for 1 week (Days 22-28)
Drug: Cilostazol · Drug: Clopidogrel
Trial period A: Cilostazol 100 mg twice daily for 1 week (Days 1-7) Trial period B: Wash out period (Days 8-14) Trial period C: Clopidogrel 75 mg once daily for 1 week (Days 15-21) Trial period D: Cilostazol 100 mg twice daily and Clopidogrel 75 mg once daily for 1 week (Days 22-28)
Drug: Cilostazol · Drug: Clopidogrel
Trial period A: Cilostazol 100 mg twice daily for 1 week (Days 1-7) Trial period B: Wash out period (Days 8-14) Trial period C: Clopidogrel 75 mg once daily for 1 week (Days 15-21) Trial period D: Cilostazol 100 mg twice daily and Clopidogrel 75 mg once daily for 1 week (Days 22-28)
Drug: Cilostazol · Drug: Clopidogrel
Ex-vivo Inhibition Of Platelet Aggregation (IPA)
The effect of ASA in combination with cilostazol and clopidogrel in combination with cilostazol on IPA was determined ex vivo in citrated platelet rich plasma (PRP) after stimulation of aggregation by low-level adenosine diphosphate (ADP) (5 micromolar \[uM\]) and arachidonic acid (AA) (500 milligrams/liter \[mg/L\]). Light transmission aggregometry (LTA) was used to measure residual aggregation (the percentage of aggregation 5 minutes after the addition of ADP or AA). Results are reported as the 95% confidence intervals for the reported geometric mean ratios (GMRs) (\[cilostazol+reference (ASA or clopidogrel)\]/reference) for IPA.
Time frame: Baseline, Visit 5 (Day 22-29)
Effects On Skin Bleeding Time (BT)
The effect of ASA in combination with cilostazol and clopidogrel in combination with cilostazol on skin BT (minutes) was determined with the Ivy method, utilizing standardized bleeding with the Surgicutt device. Results include the 95% confidence intervals for the reported GMRs (\[cilostazol+reference\]/reference) for skin BT.
Time frame: Visit 5 (Day 22-29)
| Milestone | Group 1 (CYP2C19 EM) | Group 2 (CYP2C19 EM) | Group 3 (CYP2C19 IM) | Group 4 CYP2C19 PM) | Not Assigned |
|---|---|---|---|---|---|
| Started | 20 | 19 | 19 | 17 | 2 |
| Completed | 19 | 19 | 19 | 17 | 0 |
| Not completed | 1 | 0 | 0 | 0 | 2 |
| Withdrew: Adverse event | 1 | 0 | 0 | 0 | 1 |
| Withdrew: Noncompliance | 0 | 0 | 0 | 0 | 1 |
The effect of ASA in combination with cilostazol and clopidogrel in combination with cilostazol on IPA was determined ex vivo in citrated platelet rich plasma (PRP) after stimulation of aggregation by low-level adenosine diphosphate (ADP) (5 micromolar \[uM\]) and arachidonic acid (AA) (500 milligrams/liter \[mg/L\]). Light transmission aggregometry (LTA) was used to measure residual aggregation (the percentage of aggregation 5 minutes after the addition of ADP or AA). Results are reported as the 95% confidence intervals for the reported geometric mean ratios (GMRs) (\[cilostazol+reference (ASA or clopidogrel)\]/reference) for IPA.
| ratio | Acetylsalicylic Acid - Cilostazol | Clopidogrel - Cilostazol |
|---|---|---|
| 5 µM ADP | 0.82 (0.5 to 1.37) | 1.21 (1.09 to 1.35) |
| 500 mg/L AA | 1.03 (1.01 to 1.05) | 4.42 (3.42 to 5.73) |
The effect of ASA in combination with cilostazol and clopidogrel in combination with cilostazol on skin BT (minutes) was determined with the Ivy method, utilizing standardized bleeding with the Surgicutt device. Results include the 95% confidence intervals for the reported GMRs (\[cilostazol+reference\]/reference) for skin BT.
| ratio | Acetylsalicylic Acid - Cilostazol | Clopidogrel - Cilostazol |
|---|---|---|
| Effects On Skin Bleeding Time (BT) | 1.31 (1.05 to 1.63) | 1.27 (1.09 to 1.48) |
Collected over Treatment-emergent adverse events were collected from Day 1 to Day 29. Non-serious events are listed at a 5% frequency threshold.
| Group | Deaths | Serious | Other |
|---|---|---|---|
| Cilostazol | 0/77 (0%) | 0/77 (0%) | 62/77 (80.5%) |
| Acetylsalicylic Acid | 0/20 (0%) | 0/20 (0%) | 3/20 (15%) |
| Clopidogrel | 0/55 (0%) | 0/55 (0%) | 3/55 (5.5%) |
| Acetylsalicylic Acid - Cilostazol | 0/20 (0%) | 0/20 (0%) | 10/20 (50%) |
| Clopidogrel - Cilostazol | 0/55 (0%) | 0/55 (0%) | 41/55 (74.5%) |
| Event | Cilostazol | Acetylsalicylic Acid | Clopidogrel | Acetylsalicylic Acid - Cilostazol | Clopidogrel - Cilostazol |
|---|---|---|---|---|---|
| HeadacheNervous system disorders | 60/77 | 1/20 | 2/55 | 10/20 | 38/55 |
| PalpitationsCardiac disorders | 5/77 | 0/20 | 0/55 | 2/20 | 3/55 |
| Abdominal painGastrointestinal disorders | 0/77 | 2/20 | 0/55 | 0/20 | 0/55 |
| NasopharyngitisInfections and infestations | 2/77 | 0/20 | 1/55 | 0/20 | 3/55 |
Safety Analysis Set: All subjects who received at least 1 dose of trial medication
| Age, Continuous(years) | Group 1 (CYP2C19 EM) | Group 2 (CYP2C19 EM) | Group 3 (CYP2C19 IM) | Group 4 CYP2C19 PM) | Not Assigned | Total |
|---|---|---|---|---|---|---|
| Mean | 25.8 ± 4.3 | 28.3 ± 6.5 | 25.9 ± 4.6 | 24.2 ± 4.0 | 26.5 ± 4.9 | 26.1 ± 5.0 |
| Sex: Female, Male(Participants) | Group 1 (CYP2C19 EM) | Group 2 (CYP2C19 EM) | Group 3 (CYP2C19 IM) | Group 4 CYP2C19 PM) | Not Assigned | Total |
|---|---|---|---|---|---|---|
| Female | 0 | 0 | 0 | 0 | 0 | 0 |
| Male | 20 | 19 | 19 | 17 | 2 | 77 |
| Race/Ethnicity, Customized(Participants) | Group 1 (CYP2C19 EM) | Group 2 (CYP2C19 EM) | Group 3 (CYP2C19 IM) | Group 4 CYP2C19 PM) | Not Assigned | Total |
|---|---|---|---|---|---|---|
| White | 20 | 19 | 19 | 17 | 2 | 77 |
| Region of Enrollment(Participants) | Group 1 (CYP2C19 EM) | Group 2 (CYP2C19 EM) | Group 3 (CYP2C19 IM) | Group 4 CYP2C19 PM) | Not Assigned | Total |
|---|---|---|---|---|---|---|
| Germany | 20 | 19 | 19 | 17 | 2 | 77 |
PDFs hosted by the registry, ClinicalTrials.gov.
Ran from Aug 2015 to primary completion in Mar 2018, 31 months.
Results were first posted in Oct 2021, 3 years 6 months after primary completion.
How these figures are worked out, and which studies are left out of them.
This study is completed, as verified in Sep 2021. You cannot join it, but the record below documents what was studied.
Get an email when the registry record changes — status, dates, results — or when someone posts here.
Sign in to followQuestions and observations about this study, from anyone following it. Not medical advice, and not a channel to the study team — their contact details are on the registry record.
Sign in to join the discussion. Reading takes no account; posting does. You choose a display name, and a pseudonym is the default.
Nothing here yet. If you are running this trial, taking part in it, or weighing whether to, this is the place to say so.
Studies of the drugs tested here: Aspirin · Clopidogrel
Otsuka Pharmaceutical Co., Ltd. →